Neurocrine Biosciences (NBIX) Reports Q3 Loss of $0.13

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Neurocrine Biosciences (NBIX) Reports Q3 Loss of $0.13

Neurocrine Bio. (NBIX) PT Raised to $90 at Cowen as Ingrezza Blows Past Expectations

November 2, 2017 6:26 AM EDT

Cowen analyst Phil Nadeau raised his price target on Neurocrine Bio. (NASDAQ: NBIX) to $90.00 (from $65.00) while maintaining an Outperform rating following Q3 Ingrezza sales of $45.8MM, over 4x consensus of $10.8MME, and largely reflected end-user demand.

"While Q4 will be impacted by... More